Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1097/BOR.0000000000000817 http://scihub22266oqcxt.onion/10.1097/BOR.0000000000000817 34397605!8373384!34397605     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Curr+Opin+Rheumatol 2021 ; 33 (5): 431-445 Nephropedia Template TP {{tp|p=34397605|t=2021. The role of immunomodulatory medications in the treatment of COVID-19 |pdf=|usr=}}{{34397605}} gab.com Text The role of immunomodulatory medications in the treatment of COVID-19 JO: Curr Opin Rheumatol http://www.kidney.de/pget.php?&tw=1&pmid=34397605 #FOAvip PURPOSE OF REVIEW: Given the role of inflammation in severe forms of COVID-19, glucocorticoids and disease-modifying antirheumatic drugs (DMARDs) have been assessed as potential COVID-19 therapies. RECENT FINDINGS: Randomized controlled trials (RCTs) have shown that glucocorticoids reduce mortality in severe COVID-19. RCTs of DMARDs have shown mixed results varying on intervention and inclusion criteria. DMARDs, including colchicine or biologic agents, may improve COVID-19 outcomes in specific patient populations. SUMMARY: Glucocorticoids are an effective treatment for the management of severe COVID-19. Further studies are needed to better define the patient populations who could benefit from DMARD use, as well as provide guidance regarding the timing of these interventions. Twit Text FOAVip The role of immunomodulatory medications in the treatment of COVID-19 ????Curr Opin Rheumatol http://www.kidney.de/pget.php?&tw=1&pmid=34397605 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34397605 #FOAvip English Wikipedia <ref>{{Cite pmid|34397605}}</ref> The role of immunomodulatory medications in the treatment of COVID-19 #MMPMID34397605 Sattui SE; Crow MK; Navarro-Millan I Curr Opin Rheumatol 2021[Sep]; 33 (5): 431-445 PMID34397605show ga PURPOSE OF REVIEW: Given the role of inflammation in severe forms of COVID-19, glucocorticoids and disease-modifying antirheumatic drugs (DMARDs) have been assessed as potential COVID-19 therapies. RECENT FINDINGS: Randomized controlled trials (RCTs) have shown that glucocorticoids reduce mortality in severe COVID-19. RCTs of DMARDs have shown mixed results varying on intervention and inclusion criteria. DMARDs, including colchicine or biologic agents, may improve COVID-19 outcomes in specific patient populations. SUMMARY: Glucocorticoids are an effective treatment for the management of severe COVID-19. Further studies are needed to better define the patient populations who could benefit from DMARD use, as well as provide guidance regarding the timing of these interventions. |*Antirheumatic Agents/therapeutic use[MESH] |*Arthritis, Rheumatoid/drug therapy[MESH] |*COVID-19 Drug Treatment[MESH] |Biological Factors/therapeutic use[MESH] |Humans[MESH]The role of immunomodulatory medications in the treatment of COVID-19 (epmc).pdf DeepDyve Pubget Overpricing